Bu öğeden alıntı yapmak, öğeye bağlanmak için bu tanımlayıcıyı kullanınız:
http://hdl.handle.net/11452/27330
Başlık: | Metastatic gastric cancer treatment: A little slow but worthy progress |
Yazarlar: | O'Neil, Bert H. Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Onkoloji Anabilim Dalı. Kanat, Özkan 55881548500 |
Anahtar kelimeler: | Oncology Gastric cancer Chemotherapy Targeted treatment Gastroesophageal junction adenocarcinoma Phase-II trial Chemotherapy-naive patients Folinic acid Targeted therapies 1st-line treatment Prognostic model Plus cisplatin Docetaxel Fluorouracil |
Yayın Tarihi: | Mar-2013 |
Yayıncı: | Humana |
Atıf: | Kanat, Ö ve O'Neil, BH. (2013). "Metastatic gastric cancer treatment: A little slow but worthy progress". Medical Oncology, 30(1). |
Özet: | Metastatic gastric cancer is incurable and remains one of the leading causes of cancer-related deaths around the world. Despite the significant progress in its systemic treatment, metastatic gastric cancer is still a major therapeutic challenge for oncologists. Newer chemotherapy regimens and the addition of molecularly targeted agents to chemotherapy seem to provide better clinical outcomes for patients with metastatic gastric cancer. The objective of this article is to review the current treatment approach for this formidable disease. |
URI: | https://doi.org/10.1007/s12032-013-0464-4 https://link.springer.com/article/10.1007/s12032-013-0464-4 http://hdl.handle.net/11452/27330 |
ISSN: | 1357-0560 1559-131X |
Koleksiyonlarda Görünür: | Scopus Web of Science |
Bu öğenin dosyaları:
Bu öğeyle ilişkili dosya bulunmamaktadır.
DSpace'deki bütün öğeler, aksi belirtilmedikçe, tüm hakları saklı tutulmak şartıyla telif hakkı ile korunmaktadır.